<VariationArchive RecordType="classified" VariationID="473306" VariationName="NC_000006.12:g.(?_5368551)_(5369202_?)del" VariationType="Deletion" Accession="VCV000473306" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="455121" VariationID="473306">
      <GeneList>
        <Gene Symbol="FARS2" FullName="phenylalanyl-tRNA synthetase 2, mitochondrial" GeneID="10667" HGNC_ID="HGNC:21062" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5249934" stop="5771583" display_start="5249934" display_stop="5771583" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="5261583" stop="5771815" display_start="5261583" display_stop="5771815" Strand="+" />
          </Location>
          <OMIM>611592</OMIM>
        </Gene>
        <Gene Symbol="LOC126859565" FullName="CDK7 strongly-dependent group 2 enhancer GRCh37_chr6:5368745-5369944" GeneID="126859565" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5368176" stop="5369711" display_start="5368176" display_stop="5369711" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000006.12:g.(?_5368551)_(5369202_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" innerStart="5368551" innerStop="5369202" display_start="5368551" display_stop="5369202" variantLength="652" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" innerStart="5368784" innerStop="5369435" display_start="5368784" display_stop="5369435" variantLength="652" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.(?_5368551)_(5369202_?)del" Assembly="GRCh38">
            <Expression>NC_000006.12:g.(?_5368551)_(5369202_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.(?_5368784)_(5369435_?)del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.(?_5368784)_(5369435_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000006.12:g.(?_5368551)_(5369202_?)del AND Combined oxidative phosphorylation defect type 14" Accession="RCV000526537" Version="2">
        <ClassifiedConditionList TraitSetID="9027">
          <ClassifiedCondition DB="MedGen" ID="C4755312">Combined oxidative phosphorylation defect type 14</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-07-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-07-08" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">27549011</ID>
        </Citation>
        <DescriptionHistory Dated="2020-04-09">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9027" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17497" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Combined oxidative phosphorylation defect type 14</ElementValue>
                <XRef ID="MONDO:0013986" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Combined oxidative phosphorylation deficiency 14</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">COXPD14</ElementValue>
                <XRef Type="MIM" ID="614946" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families. Infantile-onset phenotype. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of affected children die in early childhood. Later-onset phenotype. All affected individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.</Attribute>
                <XRef ID="NBK538658" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">30869852</ID>
                <ID Source="BookShelf">NBK538658</ID>
              </Citation>
              <XRef ID="319519" DB="Orphanet" />
              <XRef ID="C4755312" DB="MedGen" />
              <XRef ID="MONDO:0013986" DB="MONDO" />
              <XRef Type="MIM" ID="614946" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1251012" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-09" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1769659|MedGen:C3554168" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000652832" DateUpdated="2020-04-09" DateCreated="2017-12-26" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-07-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">27549011</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon 2 of the FARS2 gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 2 of the FARS2 gene. This is expected to result in an absent or disrupted protein product. This variant has been observed in an individual affected with early-infantile-encephalopathy (PMID: 27549011). Loss-of-function variants in FARS2 are known to be pathogenic (PMID: 22833457). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.(?_5368784)_(5369435_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Combined oxidative phosphorylation deficiency 14</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C3554168" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1251012" TraitType="Disease" MappingType="Name" MappingValue="Combined oxidative phosphorylation deficiency 14" MappingRef="Preferred">
        <MedGen CUI="C4755312" Name="Combined oxidative phosphorylation defect type 14" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

